In our EuroBiotech roundup this week, Biopharma Credit completes $762 million IPO, BerGenBio prices NOK 400 million IPO, Merck inks Avillion deal and more.

Scott Gottlieb's close links to the pharma industry have threatened to undermine his chances of becoming FDA commissioner—but he thinks he has a solution.

After Incyte and Agenus retooled their R&D pact last month, which gave the biotech access to some quick cash, it appeared that something was amiss; today,…

Upstart Tango stepped up to the dance floor today with a $55 million investment boost from VC Third Rock Ventures as it eyes a new way to help treat cancer.

Germany’s healthcare cost watchdog is continuing to push back against the European Medicines Agency’s plans to accelerate the approval of new medicines.

GSK and Warp Drive Bio are combining their drug discovery expertise in a bid to find small-molecule drugs to treat intractable disease targets.

Blueprint Medicines has filed to raise $150 million to equip itself to take its phase 1 candidates deeper into development.

Two years out from the U.K.'s scheduled EU exit date, the life science sector is increasingly confident about its post-Brexit prospects.

Ritter Pharmaceuticals has posted phase 2b/3 lactose intolerance data it claims set it up to run a confirmatory late-stage study and file for approval.